[The use of gonadotropin-releasing hormone agonist (GnRH-a) dipherelin 3,75 mg for in vitro fertilization program].
For the purpose of optimizing the superovulation stimulation and improving clinical outcome, the gonadotropin-releasing hormone (GnRH-a) agonist were successfully used in the in vitro fertilization program. Under observation were 200 women of the reproductive age with the average length of sterility 7,6+/-4,1 years. The causes of sterility were as follows: tubo-peritoneal factor 84 (42%), endometriosis 54 (27%), PCOS 24 (19%), unknown infertility 38 (19%). After the transvaginal puncture, the fertilization rate constituted 136 (67,8%). Out of 200 patients the clinical pregnancy occurred in 58 (28,7%). The obtained results indicate that the use of the GnRH agonist dipherelin 3,75 mg--in the in vitro fertilization program is an effective means of achieving the desired pregnancy.